Research programme: antibacterials - Arpida
Alternative Names: Clostridium difficile infection therapies - Arpida; AR 2474; High affinity ligands for bacterial infections - Arpida; MRSA skin infection therapies - Arpida; Topical antibacterials - ArpidaLatest Information Update: 22 Feb 2010
At a glance
- Originator Arpida
- Developer Evolva Holding SA
- Class Carbanilides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Clostridium difficile infections; Skin and soft tissue infections
Most Recent Events
- 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA
- 25 Feb 2009 Suspended - Preclinical for Bacterial infections in European Union (Topical)
- 25 Feb 2009 Suspended - Preclinical for Clostridium difficile infections in Denmark (unspecified route)